Preprocedural Mean Platelet Volume Level Is a Predictor of In-Stent Restenosis of the Superficial Femoral Artery Stents in Follow-Up

Table 1

Baseline clinical characteristics of the study patients with and without in-stent restenosis.

Characteristic	With restenosis ()	Without restenosis ()	value
Age (years)	61.5 ± 7.6	64.1 ± 9.4	0.116
Male gender, n (%)	35 (83.3%)	62 (81.6%)	0.924
Smoking, n (%)	34 (81.0%)	67 (88.2%)	0.428
Comorbidities, n (%)
Hypertension	33 (78.6%)	57 (75.0%)	0.833
Diabetes mellitus	23 (54.8%)	33 (43.4%)	0.323
Hyperlipidemia	17 (40.4%)	33 (43.4%)	0.899
Coronary artery disease	25 (59.5%)	42 (55.3%)	0.800
Heart failure	6 (14.3%)	8 (10.5%)	0.759
Previous cerebrovascular event	2 (4.8%)	2 (2.6%)	0.615
eGFR (mL/min/1.73 m^2)	62.5 ± 23.1	54.8 ± 24.5	0.259
Concomitant medical therapy, n (%)
Statin	27 (64.3%)	57 (67.1%)	0.915
Cilostazol	21 (50.0%)	32 (42.1%)	0.527
Fontaine claudication classification, n (%)			0.156
Stage I	0 (0%)	0 (0%)
Stage II	17 (40.5%)	40 (52.6%)
Stage III	17 (40.5%)	30 (39.5%)
Stage IV	8 (19.0%)	6 (7.9%)
TASC lesion classification, n (%)			0.355
Type A	8 (19.0%)	23 (30.3%)
Type B	14 (33.3%)	27 (35.5%)
Type C	17 (40.5%)	24 (31.6%)
Type D	3 (7.1%)	2 (2.6%)

eGFR = estimated glomerular filtration rate; TASC = Trans-Atlantic Inter-Society Consensus.